
|Articles|January 15, 2005
FDA approval of AMD treatment considered 'a milestone'
On Dec. 17, Eyetech Pharmaceuticals (EYET) announced FDA approval of pegaptanib sodium injection (Macugen) for the treatment of neovascular ("wet") age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Moorfields study reveals sharp rise in glaucoma burden across the UK
2
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
3
Nanoscope’s gene therapy, MCO-010 receives Sakigake and Orphan Drug Designations in Japan
4














































